NuCana PLC

$0.79 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About NuCana PLC

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The Company's pipeline includes Acelari, NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical entities derived from the nucleotide analog and 5- fluorouracil, which are used as chemotherapy agents for the treatment of cancer. Acelari is in a Phase III study for patients with biliary tract cancer. NUC-3373 is in Phase I study for the treatment of a range of patients with solid tumors and a Phase I b study for patient with metastatic colorectal cancer. Its third ProTide candidate, NUC-7738, is a nucleotide analog (3’-deoxyadenosine) and is in Phase I study for patients with solid tumors.

Stock Analysis

last close $0.79
1-mo return 32.3%
3-mo return -23.6%
avg daily vol. 102.91T
52-week high 3.32
52-week low 0.52
market cap. $33M
forward pe -
annual div. -
roe -52.2%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 29.8%
baraka

Subscribe now for daily local and international financial news

Subscribe